- Foetal growth scan
- Detail pregnancy scan
- 3-D /4-D scan for babies
- Nucheal Translucency (NT) scan for Down’s syndrome
- Abdomen - TRO liver masses, gallstones, pancreatic tumours, etc.
- Pelvis - TRO fibroid, ovarian cyst, IUD position etc.
- Kidneys & bladder - kidney stones, bladder stones etc.
- Thyroid - TRO thyroid cancers, nodules, cysts etc.
- Breast & Elastoscan(R) - TRO fibroadenoma, cysts, cancers etc.
- Scrotum - TRO seminoma, hydrocele, varicocele etc.
- Small parts - TRO Benign Prostate Hyperplasia, lymphadenopathy, cysts, joint effusion etc.
Detail Pregnancy ScanDetail pregnancy scan (also known as Foetal Anomaly Scan) is a 2D scan with the objectives of:
- to look for baby's anatomy in more details
- to find out developmental and structural abnormalities of the baby
- to determine the position of placenta.
3D / 4D Scan3D or three dimensional scan involves surface rendering and volume rendering to achieve 3D image. The objectives are:
- To provide convincing images and diagnosis of certain fetal abnormalities which will be appreciated by the patient. These fetal abnormalities include cleft lips, low set ears, facial defects, polydactyly, spina bifida, anencephaly, congenital heart defects and many others.
- To increase the psychological bonding between the parents and their unborn baby.
4D scan is a video recording of baby’s movements in the uterus.
3D/4D scan is best done at 26-29 weeks gestation.
The scan takes about 30 minutes.
Nuchal translucency & nasal bone scanThese are to increase the rate of detection for Down’s syndrome. The scan is best done between 11-14 weeks gestation.
Ultrasound is helpful in differentiating between solid and cystic mass. If it is cystic, it is almost always benign. If it is solid, 1 in 10 could be malignant. The next step is usually a biopsy.
But with elastoscan, we can further differentiate benign from malignant with 93% specificity. If it is benign, we can just re-assure and follow up the patient. If it appears malignant, then biopsy is indicated. We use BIRADS reporting system.
This we hope will reduce the number of unnecessary biopsies.